Altimmune logo.png
Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
June 23, 2024 13:45 ET | Altimmune, Inc
GAITHERSBURG, Md., June 23, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTUM clinical trial...
Altimmune logo.png
Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions
June 22, 2024 16:45 ET | Altimmune, Inc
GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its GLP-1/glucagon...
Afrezza (inhaled insulin) in use
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
June 22, 2024 08:00 ET | MannKind
INHALE-3 STUDY REVEALS POSITIVE READOUT IN HEAD-TO-HEAD COMPARISON OF INHALED INSULIN VS. USUAL CARE IN T1D; NEW DATA PRESENTED
cc.jpg
Crown Crafts to Announce Fourth Quarter and Full Year Fiscal 2024 Results on June 28, 2024
June 21, 2024 19:15 ET | Crown Crafts, Inc.
Crown Crafts to Announce Fourth Quarter and Full Year Fiscal 2024 Results on June 28, 2024
terns-color.png
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
June 21, 2024 18:30 ET | Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Trump Media Announces $69.4 Million in Initial Proceeds from Warrant Exercise
June 21, 2024 17:20 ET | Trump Media & Technology Group
SARASOTA, Fla., June 21, 2024 (GLOBE NEWSWIRE) -- Trump Media & Technology Group Corp. (NASDAQ: DJT) (“TMTG” or the “Company”)—operator of the Truth Social platform, yet another of President...
Iovance.jpg
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
June 21, 2024 17:00 ET | Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and...
argenx_logo_default.png
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
June 21, 2024 16:50 ET | argenx SE
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) First novel, precision mechanism of action in more...
ANEW MEDICAL, INC. and REDWOOD ACQUISITION CORP. ANNOUNCE CLOSING OF THEIR BUSINESS COMBINATION
June 21, 2024 16:45 ET | Redwoods Acquisition Corp.
ANEW MEDICAL, INC.’s shares and warrants are expected to begin trading on the Nasdaq Global Market under the tickers “WENA” and “WENAW”, respectively.  NEW YORK, NY, June 21, 2024 (GLOBE...